<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03167242</url>
  </required_header>
  <id_info>
    <org_study_id>CKAF156A2202</org_study_id>
    <nct_id>NCT03167242</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of KAF156 in Combination With LUM-SDF in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria</brief_title>
  <official_title>A Phase 2 Interventional, Multicenter, Randomized Open Label Study to Determine the Effective and Tolerable Dose of KAF156 and Lumefantrine Solid Dispersion Formulation in Combination, Given Once Daily for 1, 2 and 3-days to Adults and Children With Uncomplicated Plasmodium Falciparum Malaria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medicines for Malaria Venture</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to determine the most effective and tolerable dose at the shortest dosing
      regimen of the investigational drug KAF156 in combination with a solid dispersion formulation
      of lumefantrine (LUM-SDF) in adult/adolescent and pediatric patients with uncomplicated P.
      falciparum malaria.

      There is unmet medical need for anti-malarial treatment with new mechanism of action to
      reduce probability of developing resistance, and for duration shorter than 3 days of
      treatment and/or reduced pill burden.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2, 2017</start_date>
  <completion_date type="Anticipated">October 11, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 26, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PCR-corrected adequate clinical and parasitological response (ACPR)</measure>
    <time_frame>Day 28 post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AE) incidence and severity, liver and kidney function tests and electrocardiogram (ECG) abnormalities</measure>
    <time_frame>Up to Day 42 post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PCR-uncorrected ACPR</measure>
    <time_frame>Days 14, 28 and 42 post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PCR-corrected ACPR</measure>
    <time_frame>Days 14 and 42 post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of recrudescence and reinfection</measure>
    <time_frame>Days 14, 28 and 42 post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parasite and fever clearance times</measure>
    <time_frame>Up to Day 42 post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with parasitaemia</measure>
    <time_frame>12, 24 and 48 hours after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Peak Observed Concentration (Cmax)</measure>
    <time_frame>Up to Day 15 post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC)</measure>
    <time_frame>Up to Day 15 post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time after administration of a drug when the maximum plasma concentration is reached (Tmax)</measure>
    <time_frame>Up to Day 15 post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (T½)</measure>
    <time_frame>Up to Day 15 post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">512</enrollment>
  <condition>Acute Uncomplicated Plasmodium Falciparum Malaria</condition>
  <arm_group>
    <arm_group_label>KAF156 400 mg and LUM-SDF 960 mg once daily (QD) for 1 day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KAF156 800 mg and LUM-SDF 960 mg QD for 1 day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KAF156 400 mg and LUM-SDF 960 mg QD for 2 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KAF156 200 mg and LUM-SDF 480 mg QD for 3 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KAF156 400 mg and LUM-SDF 480 mg QD for 3 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KAF156 400 mg and LUM-SDF 960 mg QD for 3 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Coartem twice a day (BID) for 3 days</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cohort 7</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KAF156 200 mg and LUM-SDF 960 mg once daily for 1 day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PK Run-in Cohort</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KAF156 and LUM-SDF</intervention_name>
    <description>Exploration of different dose combinations of KAF156 and LUM-SDF. In Part B, up to three arms will be repeated in children 2 to 12 Years to confirm safety and efficacy from Part A.</description>
    <arm_group_label>KAF156 400 mg and LUM-SDF 960 mg once daily (QD) for 1 day</arm_group_label>
    <arm_group_label>KAF156 800 mg and LUM-SDF 960 mg QD for 1 day</arm_group_label>
    <arm_group_label>KAF156 400 mg and LUM-SDF 960 mg QD for 2 days</arm_group_label>
    <arm_group_label>KAF156 200 mg and LUM-SDF 480 mg QD for 3 days</arm_group_label>
    <arm_group_label>KAF156 400 mg and LUM-SDF 480 mg QD for 3 days</arm_group_label>
    <arm_group_label>KAF156 400 mg and LUM-SDF 960 mg QD for 3 days</arm_group_label>
    <arm_group_label>KAF156 200 mg and LUM-SDF 960 mg once daily for 1 day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Coartem</intervention_name>
    <description>Control arm</description>
    <arm_group_label>Coartem twice a day (BID) for 3 days</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Part A: male and female patients ≥ 12 years and with a body weight ≥ 35.0 kg. Part B:
             after determining the effective/tolerated doses and regimens in adolescent and adult
             patients, male and female patients ≥ 2 and &lt; 12 years and with a body weight ≥ 10.0 kg
             will be included.

          -  Microscopic confirmation of P. falciparum by Giemsa-stained thick and thin films.

          -  P. falciparum parasitaemia of more than 1000 and less than 150 000 parasites/µL at the
             time of pre-screening (i.e., Study Visit 1).

          -  Axillary temperature ≥ 37.5 ºC or oral/tympanic/rectal temperature ≥ 38.3 ºC; or
             similar history of fever during the previous 24 hours (history of fever must be
             documented).

          -  Written informed consent must be obtained before any assessment is performed. If the
             patient is unable to read and write, then a witnessed consent according to local
             ethical standards is permitted. Patients &lt; 18 years old, who are capable of providing
             assent, must provide assent with parental/legal guardian consent or as per local
             ethical guidelines.

        Exclusion Criteria:

          -  Mixed Plasmodium infections.

          -  Signs and symptoms of severe malaria according to WHO (World Health Organization) 2015
             criteria unless characterized by high parasitaemia only.

          -  Patients with concurrent febrile illnesses (e.g., typhoid fever).

          -  Severe vomiting, defined as more than 3 times in the 24 hours prior to inclusion in
             the study or severe diarrhea defined as more than 3 watery stools per day.

          -  Pregnant or nursing (lactating) women.

          -  Clinically relevant abnormalities of electrolyte balance which require correction,
             e.g., hypokalemia, hypocalcemia or hypomagnesemia.

          -  Anemia (Hemoglobin level &lt; 8 g/dL).

          -  Patients with prior antimalarial therapy or antibiotics with antimalarial activity
             within minimum of their five (5) plasma half-lives (or within 4 weeks of screening if
             half-life is unknown).

          -  History or family history of long QT syndrome or sudden cardiac death, or any other
             clinical condition known to prolong the QTc (heart rate-corrected QT) interval, such
             as history of symptomatic cardiac arrhythmias, clinically relevant bradycardia or
             severe heart disease.

          -  Any surgical or medical condition which might significantly alter the absorption,
             distribution, metabolism, or excretion of drugs, or which may jeopardize the patient
             in case of participation in the study. The investigator should make this determination
             in consideration of the patient's medical history and/or clinical or laboratory
             evidence of any of the following:

          -  AST/ALT &gt; 2 x the upper limit of normal range (ULN), regardless of the level of total
             bilirubin

          -  AST/ALT &gt; 1.5 and ≤ 2 x ULN and total bilirubin is &gt; ULN

          -  Total bilirubin &gt; 2 x ULN, regardless of the level of AST/ALT
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lambarene</city>
        <country>Gabon</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Banjul</city>
        <zip>273</zip>
        <country>Gambia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Siaya</city>
        <zip>2300</zip>
        <country>Kenya</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bamako</city>
        <country>Mali</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ratchaburi</city>
        <zip>70180</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tak</city>
        <zip>63140</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Binh Phuoc</city>
        <state>VNM</state>
        <zip>830000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Gabon</country>
    <country>Gambia</country>
    <country>Kenya</country>
    <country>Mali</country>
    <country>Thailand</country>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2017</study_first_submitted>
  <study_first_submitted_qc>May 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 25, 2017</study_first_posted>
  <last_update_submitted>May 7, 2018</last_update_submitted>
  <last_update_submitted_qc>May 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Falciparum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Artemether-lumefantrine combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

